<DOC>
	<DOCNO>NCT00459186</DOCNO>
	<brief_summary>The purpose study evaluate safety optimal dose RAD001 docetaxel plus prednisone men hormone refractory , metastatic prostate cancer ( Phase I ) . Once appropriate dose reach , purpose determine response rate docetaxel plus RAD001 ( Phase II ) .</brief_summary>
	<brief_title>The Use RAD001 With Docetaxel Treatment Metastatic , Androgen Independent Prostate Cancer</brief_title>
	<detailed_description>- Patients designate one two group base upon result FDG-PET scan . - A patient baseline positive scan serum drawn baseline serum proteomics assessment treat RAD001 daily two week . On day 10-14 , another FDG-PET scan serum assessment perform . An optional bone marrow biopsy may also do . On day 15 , patient enter Phase I portion trial current enrolling dosage Phase I complete patient enter Phase II . - A patient positive scan enter directly Phase I trial Phase II depend trial currently enrol . - Phase I trial patient weekly laboratory evaluation clinical evaluation every three week . - Phase II trial patient laboratory evaluation day one day eight clinical evaluation every three week . - The maximum duration trial one year therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Adenocarcinoma prostate radiographic evidence metastatic disease . Willingness undergo baseline tumor biopsy . Castrate level testosterone ( testosterone &lt; 50 ng/dL ) androgen deprivation therapy ( ADT ) evidence progression ADT . GnRH therapy continue baseline Patient must suspect tumor area safe biopsy . Other prior hormonal intervention experimental approach allow . These therapy must discontinue minimum 28 day cancer progression . Prior concurrent use bisphosphonates allow . One prior nontaxane chemotherapy allow ≥ 3 week since major surgery ; ≥ 4 week since radiotherapy ; ≥ 8 week since prior strontium89 samarium 153 Performance Status : ECOG 0 1 ANC &gt; 1,500/_l ; platelet &gt; 100,000/_l ; total Bilirubin &lt; upper limit normal ; AST ALT &lt; 3 x upper limit normal ; creatinine &lt; 1.5 x upper limit normal ; total fasting cholesterol &lt; 350 mg/dl ; total triglyceride &lt; 300 mg/dl Ongoing oral steroid use . Patients history oral steroid use eligible long steroid discontinue prior study entry . Ongoing topical and/or inhale steroid use allow . Prior taxane chemotherapy Prior mTOR inhibitor ( RAD001 , rapamycin , CCI779 ) Currently active second malignancy nonmelanoma skin cancer . Ongoing peripheral neuropathy Grade 2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>RAD001</keyword>
	<keyword>mTOR inhibition</keyword>
	<keyword>docetaxel</keyword>
</DOC>